Clinical trial · Interventional
Imaging Guided Cementoplasty for Pelvic Bone Metastasis
Immediate and Short-term Outcomes of Imaging Guided Percutaneous Cementoplasty for Pelvic Bone Metastases
NCT06231628CI-TRIAL-00073403unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aimed to summarize the immediate operative and short-term efficacy and safety outcomes of percutaneous cementoplasty for pelvic metastases
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Imaging Guided | — | UNRESOLVED | — |
| Pelvic Bone Metstasis | — | UNRESOLVED | — |
| Percutaneous Cementoplasty | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Percutaneous cementoplasty | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Patients
- description
- A single arm with patients with advanced cancer who have all of the following: 1. refractory pain and/or gait disturbance caused by pelvic bone metastasis, did not respond to conservative treatment. 2. osteolytic lesion (in predominance) suitable for the pain. 3. limited life expectancy (less than 3 years) or stopping medical treatment. Exclusion criteria: There are no absolute contraindications for the procedure; however, the relative contraindications are: 1. patients in poor condition with an expected survival period of less than 3 months. 2. patients with stable course, with long life expectancy (more than 3 years) or those considered candidates for major pelvic surgery including tumor removal and hip arthroplasty. 3. presence of bone destruction with soft tissue mass contaminating important organs, nerves and blood vessels (improvement is not expected). 4. Patients refusing to give a written consent to the study protocol.
- interventionNames
- Procedure: Percutaneous cementoplasty
Primary outcomes (1)
- measure
- Pain reduction
- timeFrame
- 3 months
- description
- To evaluate pain, the numerical pain score (NRS) will be used. The NRS is an 11-point numerical scale ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst possible pain (Figure 3) and pain is classified as mild pain if 1-4 points (tolerable), moderate if 5-6 points and severe if 7-10 points. NRS has been shown to be particularly reliable especially among patients with low health literacy. The NRS is also simple to score, and can be administered both orally and in written form.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. refractory pain and/or gait disturbance caused by pelvic bone metastasis, did not respond to conservative treatment. 2. osteolytic lesion (in predominance) suitable for the pain. 3. limited life expectancy (less than 3 years) or stopping medical treatment Exclusion Criteria: There are no absolute contraindications for the procedure; however, the relative contraindications are: 1. patients in poor condition with an expected survival period of less than 3 months. 2. patients with stable course, with long life expectancy (more than 3 years) or those considered candidates for major pelvic surgery including tumor removal and hip arthroplasty. 3. presence of bone destruction with soft tissue mass contaminating important organs, nerves and blood vessels (improvement is not expected). 4. Patients refusing to give a written consent to the study protocol.
References
Publications (0)
Data not yet available
No reference posted for this study.